Maverix Biomics

maverixbio.com

Maverix Biomics brings together decades of experience and expertise in biologic research, bioinformatics, and enterprise application software development from many of today’s leading research institutions and technology companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

C-LECTA CONTINUES ITS GROWTH IN 2021 AND SEES ITSELF EXCELLENTLY POSITIONED FOR THE FUTURE WITH THE ENESYZ TECHNOLOGY PLATFORM

c-LEcta | December 20, 2021

news image

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, continued its growth in 2021. The high expectations for the fiscal year have been fully met and were even significantly exceeded. Thus, the management expects annual revenue in the range of EUR 20 million, which equates to a doubling of last year’s result. With an expanded team, further investments in the product range and the ENESYZ technology platform are expected to keep ...

Read More

MedTech

AVENGE BIO ANNOUNCES PEER-REVIEWED PUBLICATION ON PRECLINICAL PROOF-OF-CONCEPT FOR LOCOCYTE™ PLATFORM TECHNOLOGY IN MALIGNANT MESOTHELIOMA

Avenge Bio, Inc. | August 23, 2022

news image

Avenge Bio, Inc. a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte™ for the treatment of pleural malignant mesothelioma. The manuscript, entitled "Activation of adaptive...

Read More

Research

BIO-TECHNE AND CARTERRA INITIATE A CLINICAL RESEARCH COLLABORATION FOR COVID-19 VARIANT ANALYSIS

Bio-Techne Corporation | September 08, 2021

news image

Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening and characterization, today announced a clinical research collaboration studying COVID-19 variants. New variants, such as Delta, can be more easily transmitted and more likely to evade the immune response of vaccinated or previously infected people. To assess immune responses to ...

Read More

Medical

BAKAR LABS AND THE CYSTIC FIBROSIS FOUNDATION SUPPORT ENTREPRENEURS TO DEVELOP NEW GENETIC THERAPIES FOR CF

Bakar Labs | April 19, 2022

news image

Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis Foundation to accelerate the application of new technologies for the treatment of cystic fibrosis. The CF Foundation is sponsoring a "Golden Ticket" competition at the new incubator and is encouraging companies with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may work in CF to apply. Applications open M...

Read More
news image

Cell and Gene Therapy

C-LECTA CONTINUES ITS GROWTH IN 2021 AND SEES ITSELF EXCELLENTLY POSITIONED FOR THE FUTURE WITH THE ENESYZ TECHNOLOGY PLATFORM

c-LEcta | December 20, 2021

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, continued its growth in 2021. The high expectations for the fiscal year have been fully met and were even significantly exceeded. Thus, the management expects annual revenue in the range of EUR 20 million, which equates to a doubling of last year’s result. With an expanded team, further investments in the product range and the ENESYZ technology platform are expected to keep ...

Read More
news image

MedTech

AVENGE BIO ANNOUNCES PEER-REVIEWED PUBLICATION ON PRECLINICAL PROOF-OF-CONCEPT FOR LOCOCYTE™ PLATFORM TECHNOLOGY IN MALIGNANT MESOTHELIOMA

Avenge Bio, Inc. | August 23, 2022

Avenge Bio, Inc. a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte™ for the treatment of pleural malignant mesothelioma. The manuscript, entitled "Activation of adaptive...

Read More
news image

Research

BIO-TECHNE AND CARTERRA INITIATE A CLINICAL RESEARCH COLLABORATION FOR COVID-19 VARIANT ANALYSIS

Bio-Techne Corporation | September 08, 2021

Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening and characterization, today announced a clinical research collaboration studying COVID-19 variants. New variants, such as Delta, can be more easily transmitted and more likely to evade the immune response of vaccinated or previously infected people. To assess immune responses to ...

Read More
news image

Medical

BAKAR LABS AND THE CYSTIC FIBROSIS FOUNDATION SUPPORT ENTREPRENEURS TO DEVELOP NEW GENETIC THERAPIES FOR CF

Bakar Labs | April 19, 2022

Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis Foundation to accelerate the application of new technologies for the treatment of cystic fibrosis. The CF Foundation is sponsoring a "Golden Ticket" competition at the new incubator and is encouraging companies with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may work in CF to apply. Applications open M...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us